These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37766102)

  • 41. Automated antigen assays display a high heterogeneity for the detection of SARS-CoV-2 variants of concern, including several Omicron sublineages.
    Osterman A; Krenn F; Iglhaut M; Badell I; Lehner A; Späth PM; Stern M; Both H; Bender S; Muenchhoff M; Graf A; Krebs S; Blum H; Grimmer T; Durner J; Czibere L; Dächert C; Grzimek-Koschewa N; Protzer U; Kaderali L; Baldauf HM; Keppler OT
    Med Microbiol Immunol; 2023 Oct; 212(5):307-322. PubMed ID: 37561226
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
    Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
    Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants.
    Springer DN; Bauer M; Medits I; Camp JV; Aberle SW; Burtscher C; Höltl E; Weseslindtner L; Stiasny K; Aberle JH
    NPJ Vaccines; 2023 Aug; 8(1):110. PubMed ID: 37542025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
    Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
    Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
    bioRxiv; 2022 Dec; ():. PubMed ID: 36482971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection.
    Wang X; Zhang M; Wei K; Li C; Yang J; Jiang S; Zhao C; Zhao X; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Zhang W; Xie F; Wang P; Zhang Y
    Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
    Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
    Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters.
    Ying B; Darling TL; Desai P; Liang CY; Dmitriev IP; Soudani N; Bricker T; Kashentseva EA; Harastani H; Schmidt AG; Curiel DT; Boon ACM; Diamond MS
    bioRxiv; 2023 May; ():. PubMed ID: 37205450
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population.
    Sutandhio S; Furukawa K; Kurahashi Y; Marini MI; Effendi GB; Hasegawa N; Ishimaru H; Nishimura M; Arii J; Mori Y
    J Infect Public Health; 2023 Jul; 16(7):1064-1072. PubMed ID: 37196370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection.
    Widyasari K; Jang J; Kang T; Kim S
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
    Ao D; He X; Hong W; Wei X
    MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion.
    Li P; Liu Y; Faraone J; Hsu CC; Chamblee M; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Li J; Gumina RJ; Liu SL
    bioRxiv; 2024 Mar; ():. PubMed ID: 38559216
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques.
    Hashimoto M; Aoe S; Kawazu Y; Seki NM; Hashimoto K; Yoshihara K; Homma T; Sonoyama T; Omoto S
    Vaccine; 2022 Dec; 40(52):7520-7525. PubMed ID: 36372670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2.
    Qu P; Evans JP; Faraone J; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    bioRxiv; 2022 Oct; ():. PubMed ID: 36299423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
    Vergori A; Matusali G; Lepri AC; Cimini E; Fusto M; Colavita F; Gagliardini R; Notari S; Mazzotta V; Mariotti D; Cicalini S; Girardi E; Vaia F; Maggi F; Antinori A;
    Int J Infect Dis; 2023 Sep; 134():195-199. PubMed ID: 37343783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
    Valanparambil RM; Lai L; Johns MA; Davis-Gardner M; Linderman SL; McPherson TO; Chang A; Akhtar A; Gamarra ELB; Matia H; McCook-Veal AA; Switchenko J; Nasti TH; Green F; Saini M; Wieland A; Pinsky BA; Solis D; Dhodapkar MV; Carlisle J; Ramalingam S; Ahmed R; Suthar MS
    NPJ Vaccines; 2023 Nov; 8(1):179. PubMed ID: 37990024
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
    Chalkias S; Whatley JL; Eder F; Essink B; Khetan S; Bradley P; Brosz A; McGhee N; Tomassini JE; Chen X; Zhao X; Sutherland A; Shen X; Girard B; Edwards DK; Feng J; Zhou H; Walsh S; Montefiori DC; Baden LR; Miller JM; Das R
    Nat Med; 2023 Sep; 29(9):2325-2333. PubMed ID: 37653342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.
    Gayed J; Diya O; Lowry FS; Xu X; Bangad V; Mensa F; Zou J; Xie X; Hu Y; Lu C; Cutler M; Belanger T; Cooper D; Koury K; Anderson AS; Türeci Ö; Şahin U; Swanson KA; Modjarrad K; Gurtman A; Kitchin N;
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England.
    Kirsebom FCM; Harman K; Lunt RJ; Andrews N; Groves N; Abdul Aziz N; Hope R; Stowe J; Chand M; Ramsay M; Dabrera G; Kall M; Bernal JL
    Lancet Reg Health Eur; 2023 Dec; 35():100755. PubMed ID: 38115965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.